Filtered By:
Condition: Atrial Fibrillation
Countries: USA Health

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 257 results found since Jan 2013.

Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis
CONCLUSIONS: This real-world analysis showed DOACs to be associated with lower risk of stroke/SE and major bleeding, and lower medical costs compared to warfarin. Among them, only apixaban appears to be associated with a significantly lower risk of all three outcomes collectively: stroke/SE, major bleeding, and lower related medical costs compared to warfarin.PMID:35993487 | DOI:10.1080/03007995.2022.2115772
Source: Current Medical Research and Opinion - August 22, 2022 Category: Research Authors: Alpesh Amin Allison Keshishian Dionne M Hines Oluwaseyi Dina Hannah Le Lisa Rosenblatt Xianchen Liu Qisu Zhang Lien Vo Source Type: research

P-030 Mechanical thrombectomy in medium vessel occlusions using the novel aspiration MIVI Q catheters: an international multicenter experience
ConclusionsTreatment of MeVO patients with Q catheters resulted in optimal angiographic and clinical outcomes. Though angiographic results were similar between primary and secondary MeVOs, the first had less severe presentation and better outcomes at 90-days than the latter.Disclosures A. Monteiro: None. L. Makalanda: None. J. Wareham: None. J. Jones: None. P. Dhillon: None. P. Bhogal: None. W. Brinjikji: None. M. Mokin: None. A. Siddiqui: 1; C; Co-investigator for NIH – 1R01EB030092–01, Project Title: High Speed Angiography at 1000 frames per second; Mentor for Brain Aneurysm Foundation Carol W. Harvey Chair o...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Monteiro, A., Makalanda, L., Wareham, J., Jones, J., Dhillon, P., Bhogal, P., Brinjikji, W., Mokin, M., Siddiqui, A. Tags: SNIS 19th annual meeting oral poster abstracts Source Type: research

Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database
ConclusionsAlthough OAC therapy prescription is the standard of care for stroke prevention in AF patients, its overall utilization is still low among Medicare patients  ≥ 65 years old, with specific patient characteristics that predict underutilization.
Source: Journal of Interventional Cardiac Electrophysiology - July 9, 2022 Category: Cardiology Source Type: research

Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
CONCLUSION: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.PMID:35726631 | DOI:10.1161/CIRCULATIONAHA.122.058575
Source: Circulation - June 21, 2022 Category: Cardiology Authors: Derek S Chew Yanhong Li Patricia A Cowper Kevin J Anstrom Jonathan P Piccini Jeanne E Poole Melanie R Daniels Kristi H Monahan Linda Davidson-Ray Tristram D Bahnson Hussein R Al-Khalidi Kerry L Lee Douglas L Packer Daniel B Mark CABANA Investigators Source Type: research

Left atrial appendage closure using WATCHMAN device in chronic kidney disease and end ‐stage renal disease patients
ConclusionPatients with and without ESRD/CKD who undergo LAA occlusion with Watchman have similar procedure related, in-hospital mortality, and complications.
Source: Pacing and Clinical Electrophysiology : PACE - June 9, 2022 Category: Cardiology Authors: Shakeel Jamal, Mohsin Sheraz Mughal, Asim Kichloo, Ehizogie Edigin, Muhammad Zia Khan, Abdul Mannan Khan Minhas, Muzaffar Ali, Khalil Kanjwal Tags: DEVICES (DIRECT VIA EEO) Source Type: research

One Year Outcomes of Atrial Fibrillation Ablation: Contemporary Analysis of the United States Nationwide Readmission Database
Conclusion: In this study, CA for AF was associated with significantly lower AF and stroke-related admissions, but not to HF or all cause readmission. Better outcomes were seen among males, younger patients and in patients with less comorbidities and low CHA ₂DS₂-VASc scores.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - June 4, 2022 Category: Cardiology Authors: Lingling Wu, Bharat Narasimhan, Kirtipal Bhatia, Ellen Wu, Pengyang Li, Kam S Ho, Arti N Shah, Bharat K. Kantharia Tags: ORIGINAL ARTICLE Source Type: research

Left atrial appendage closure using WATCHMAN device in chronic kidney disease and end stage renal disease patients
ConclusionPatients with and without ESRD/CKD who undergo LAA occlusion with Watchman have similar procedure related, in-hospital mortality and complications.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - May 28, 2022 Category: Cardiology Authors: Shakeel Jamal, Mohsin Sheraz Mughal, Asim Kichloo, Ehizogie Edigin, Muhammad Zia Khan, Abdul Mannan Khan Minhas, Muzaffar Ali, Khalil Kanjwal Tags: DEVICES Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

State-of-the-Art Review: Evidence on Red Meat Consumption and Hypertension Outcomes
Am J Hypertens. 2022 May 13:hpac064. doi: 10.1093/ajh/hpac064. Online ahead of print.ABSTRACTHypertension (HTN) is a well-established risk factor for cardiovascular diseases (CVD), including ischemic heart disease, stroke, heart failure and atrial fibrillation. The prevalence of HTN, as well as mortality rates attributable to HTN, continue to increase, particularly in the United States and among Black populations. The risk of HTN involves a complex interaction of genetics and modifiable risk factors, including dietary patterns. In this regard, there is accumulating evidence that links dietary intake of red meat with a high...
Source: American Journal of Hypertension - May 13, 2022 Category: Cardiology Authors: Tara Shrout Allen Harpreet S Bhatia Alexis C Wood Shabnam R Momin Matthew A Allison Source Type: research

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010 –2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 6, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the united states, 2010 ‐2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 3, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: RESEARCH ARTICLE Source Type: research